41 results about "Hypromellose acetate succinate" patented technology

The invention relates to an enteric-coated tilmicosin slow-release micro-capsule preparation and a preparation method thereof and belongs to the field of tilmicosin preparations. The enteric-coated tilmicosin slow-release micro-capsule preparation provided by the invention comprises an inner core layer and a coating layer, wherein the inner core layer comprises tilmicosin raw powder and an auxiliary material; the auxiliary material comprises one or more than one of stearic acid, glycerin monostearate, stearyl alcohol, saturated triglyceride, monoglyceride and paraffin; and the coating layer is made from one or more than one of cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, acrylic resin, polyvinyl acetate phthalate and acetic hydroxypropyl methylcellulose succinate. The preparation method comprises the following steps of: carrying out primary coating on the tilmicosin raw powder and the auxiliary material, carrying out secondary coating by using the materials of the coating layer, and drying to obtain the finished product. According to the invention, the tilmicosin is coated by using high polymer materials and the coated tilmicosin micro-capsule is undissolved in acid environment and slowly dissolved in alkaline environment of enteric canal, so that the purpose of slow release is achieved and the action time of the tilmicosin is prolonged.

The invention discloses a method for preparing hydroxypropyl methylcellulose acetate succinate. The method comprises the following two steps: an esterification step: adding hydroxypropyl methylcellulose, acetic acid, anhydrous sodium acetate, acetic anhydride, succinic anhydride and a catalyst in proportion to a reaction vessel, and heating and stirring to undergo an esterification reaction; a purification step: after the completion of the reaction, slowly pouring a product into water while stirring, washing the product, crushing and drying to obtain the hydroxypropyl methylcellulose acetate succinate, wherein a three-step temperature raising method is adopted by heating. The method provided by the invention has the advantages of simplicity in industrial production operation, less by-products, mild reaction conditions, and adjustability of viscosity within 100-10000mpa.s, and is suitable for different application requirements.

The invention relates to a preparation method of taste-masked suspension granules of Gegenqinlian decoction. The preparation method comprises the following steps of 1, taking appropriate amounts of dispensing granules of three traditional Chinese medicines comprising radix puerariae, coptis chinensis and scutellaria baicalensis and respectively carrying out coating processes in a fluidized bed through adopting one or more polymers as coating materials to obtain coated granules for next use, 2, taking an appropriate amount of at least one suspending agent, mixing uniformly the at least one suspending agent and radix glycyrrhizae preparata dispensing granules, then adding an appropriate amount of an adhesive into the mixture to prepare into granules by a wet method, drying the prepared granules in an oven, and then spraying an appropriate amount of an ethanol solution as an aromatic to obtain suspending agent-containing radix glycyrrhizae preparata dispensing granules after ethanol is volatilized, and 3, weighing appropriate amounts of the suspending agent-containing radix glycyrrhizae preparata dispensing granules and the coated granules containing radix puerariae, coptis chinensisand scutellaria baicalensis, mixing well, and carrying out sub-packaging to obtain the taste-masked suspension granules of Gegenqinlian decoction, wherein the one or more polymers as coating materials are selected from enteric-coated polyacrylic resin, hypromellose acetate succinate and hydroxypropyl methylcellulose phthalate. The invention provides the preparation method of the taste-masked suspension granules of Gegenqinlian decoction. The preparation method is also suitable for taste masking of a traditional Chinese medicine with a bitter taste or a fishy smell.

The invention relates to a method for preparing hydroxypropyl methylcellulose acetate succinate, and belongs to the field of chemical synthesis. The method comprises the following steps of: (1) preparing 100 weight parts of hydroxypropyl methylcellulose, 10 to 50 weight parts of anhydrous sodium acetate and 20 to 60 weight parts of glacial acetic acid, mixing, and adding 25 to 75 weight parts of succinic anhydride and 30 to 50 weight parts of acetic anhydride; (2) performing microwave radiation on the mixture obtained in the step (1) for 4 to 7 minutes under the power of 400 to 750 kw, and cooling naturally to the temperature of between 50 and 70 DEG C to obtain a reaction product; (3) pouring the reaction product into water, and after precipitating the reaction product completely, washing and performing suction filtration until precipitated liquid is neutral; and (4) drying filter cakes obtained by the suction filtration under vacuum to obtain the hydroxypropyl methylcellulose acetate succinate. The method is high in speed of acylation reaction, short in reaction time and few in byproducts.

The invention discloses an aprepitant oral pharmaceutical preparation. The aprepitant oral pharmaceutical preparation comprises 15wt%-25wt% of aprepitant, 45wt%-75wt% of hydroxypropyl methylcellulose phthalate/hydroxypropyl methylcellulose acetate succinate, 10wt%-25wt% of microcrystalline cellulose, lactose or mannitol, 2wt%-8wt% of low-substituted hydroxypropyl cellulose as well as croscarmellose sodium and/or crospovidone, 0-2wt% of silicon dioxide and/or talc and 0-2wt% of magnesium stearate. The pharmaceutical preparation can be prepared in a form of tablets or capsules andhas high stability and good bioavailability.

The invention discloses ziprasidone hydrochloride solid dispersible tablets and a hot melt extrusion method thereof. Based on ziprasidone hydrochloride as a main component, one or two of mixed carriers of copolyvidone S630 or HPMCAS-HF (hydroxypropyl methylcellulose acetate succinate) as a base, a coating material is added, and the glass transition temperature of an extruded mixture can also be reduced; then, a surfactant is added. The ziprasidone hydrochloride solid dispersible tablets are prepared through steps as follows: the raw and auxiliary materials are evenly mixed by a three-dimensional mixing machine, extruded by a hot melt extruder at a high temperature and ground into powder with proper size; the powder is then mixed with a fixed quantity of filler, disintegrant and lubricant sufficiently and uniformly, and direct tableting is preformed, and the ziprasidone hydrochloride solid dispersible tablets are prepared. The prepared ziprasidone hydrochloride solid dispersible tabletshave the advantages that the problem of poor in-vitro dissolution of ziprasidone hydrochloride is solved, bioavailability of ziprasidone hydrochloride under the condition of empty stomach is improved, and the treatment effect of the tablets is improved finally.

The invention discloses a posaconazole solid dispersion composition capable of inhibiting separation by crystallization as well as a preparation method thereof, and relates to the field of posaconazole preparations. The posaconazole solid dispersion composition contains acrylic resin and posaconazole serving as an active component. The research of the invention discovers that compared with hydroxypropyl methylcellulose acetate succinate (HPMCAS) serving as a carrier material, the posaconazole solid dispersion composition taking acrylic resin as a carrier material has the following advantages:after a posaconazole crystal seed is induced in the intestinal environment simulated pH 6.8 dissolution test, the crystallization inhibiting capability is higher and the medicine can be absorbed in vivo better.

Provided are hypromellose acetate succinates (HPMCAS) for use as a hot-melt extrusion carrier having a volume average particle size (D₅₀) of from 70 to 300 as measured by dry laser diffraction and a loose bulk density of from 0.25 to 0.40 g/cm³; and a hot-melt extrusion composition comprising the HPMCAS and a drug. Also provided is a method for producing a hot-melt extrudate including the steps of: hot-melting the hot-melt extrusion composition at a hot-melt temperature equal to or higher than a melting temperature of the HPMCAS, or at a hot-melt temperature equal to or higher than a temperature at which both of the HPMCAS and the drug become melt; and extruding the hot-melted composition.

The disclosure includes tablet cores comprising Sovaprevir and a crystal growth inhibitor selected from hydroxypropyl methyl cellulose (HPMC), HPC (hydroxypropyl cellulose), hypromellose acetate succinate (HPMCAS), polyvinyl pyrrolidone (PVP), copovidone (PVP-VA), a copolymer of methacrylic acid and ethyl acrylate, or any combination of the foregoing, wherein ratio of Sovaprevir to crystal growth inhibitor is from about 40:60 (w/w) to about 60:40 (w/w). The disclosure further includes film coated tables. The disclosure also includes methods of treating HCV with the tablets described herein.

The invention discloses an antifungal drug posaconazole solid dispersion, a preparation method and an application. The solid dispersion comprises posaconazole and an enteric-coating material, wherein the enteric-coating material is hydroxypropyl methylcellulose acetate succinate. A formulated amount of the posaconazole and the hydroxypropyl methylcellulose acetate succinate is weighed, mixed and added into mixed solution with one or two of acetone or ethyl alcohol solution, and spin flash drying is performed after dissolution to obtain the posaconazole solid dispersion. The dissolution rate of the posaconazole can be increased by the hydroxypropyl methylcellulose acetate succinate, absorption of the posaconazole is promoted, and bioavailability of the posaconazole is improved.

A composition for an enteric hard capsule by taking advantage of conventionally unknown thermal gelation characteristics of a neutralized aqueous solution of an enteric polymer, so as to obtain an enteric capsule having sufficient water and acid resistances. More specifically, the composition has hypromellose acetate succinate having a molar substitution with an acetyl group per anhydroglucose unit of 0.6 to 0.8 and a ratio of the molar substitution with an acetyl group to a molar substitution with a succinyl group per anhydroglucose unit of 2.0 to 4.0, a neutralizer, and water method produces an enteric hard capsule having the steps of: immersing a core pin heated at 50 to 80° C. in the composition, taking the immersed core pin out of the composition, and drying a gel layer of the hypromellose acetate succinate formed on the taken-out core pin.

A process for preparing spray dried solid dispersions of (S)—N-(3-(6-isopropoxypyridin-3-yl)-1H4ndazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide amorphous free base and hypromellose acetate succinate for pharmaceutical preparations including pharmaceutical capsule preparations.

An injection molding composition is capable of being injection-molded easily at a temperature lower than that of a conventional composition, and an injection molded product has improved strength. More specifically, an injection molding composition containing HPMCAS has a hydroxypropoxy molar substitution of 0.40 or more. In addition, a method produces an injection molded product including a step of injecting into a mold the injection molding composition at from 50 to 250° C.

The invention relates to a special multi-stage controlled-release compound microbial fertilizer for rice and a preparation method thereof. The special multi-stage controlled-release compound microbial fertilizer structurally comprises a rice booting fertilizer layer, a dry farmland nutrient microbial agent layer, a water-soluble sensitive layer with the pH value larger than or equal to 6, a rice seedling fertilizer layer with the pH value smaller than 6, a paddy field biocontrol microbial agent layer, a hydrolysis coating layer and a decomposed microorganism/organic matter fertilizer layer from inside to outside in sequence. Wherein the water-soluble sensitive layer with the pH value greater than or equal to 6 is made of one or more of cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate, a methacrylic acid copolymer L100, a methacrylic acid copolymer S100 and a methacrylic acid copolymer L100; wherein the hydrolysis coating layer is made of one or more of Arabic gum, gelatin and peach gum. The compound microbial fertilizer disclosed by the invention can release required nutrients according to soil environment control in different growth periods of rice, meets nutrient requirements of the whole growth period of the rice, and improves the utilization rate of the fertilizer.

Provided are HPMCAS powder having high solubility when dissolved in a solvent and being capable of suppressing generation of undissolved materials; and a method for producing the powder. More specifically, provided is hypromellose acetate succinate powder having an average ratio of L to D of from 2.0 to 3.0, wherein L and D mean maximum and minimum diameters of each particle, respectively. Also provided is a method for producing a hypromellose acetate succinate, comprising the steps of: dissolving hypromellose powder in a solvent, esterifying the dissolved hypromellose with succinic anhydride and acetic anhydride in the presence of a catalyst to obtain a reaction mixture, and mixing the reaction mixture with water to precipitate hypromellose acetate succinate, wherein the reaction mixture just before being mixed with the water has a viscosity of from 100 to 200 Pa·s.

The invention discloses a solid dispersion and a pharmaceutical composition, and relates to the technical field of medicines. The solid dispersion contains an active drug and a carrier material, wherein the active drug is a compound in a formula 1 or formula 2; and the carrier material is any one of hydroxypropyl methylcellulose acetate succinate and hydroxypropyl methylcellulose phthalate. The solid dispersion can improve the solubility and absorption properties of the compound in the formula 1 or formula 2, thereby reducing the clinical dosage. Characterization shows that the compound in theformula 1 or formula 2 is dispersed in the carrier material in an amorphous form and still exists in an amorphous state after being placed for 3 months under an acceleration condition (40 DEG C/75% RH), and the performance is stable. A preparation prepared from the solid dispersion can greatly reduce the influence of environmental temperature, humidity and the like on product dissolution and bioavailability in the processes of production, transportation, storage and the like of medicines.